Effect of protein kinase cβ inhibition on renal hemodynamic function and urinary biomarkers in humans with type 1 diabetes: A pilot study

Diabetes Care

Volumn 32, Issue 1, 2009, Pages 91-93

  Cherney, David Z I ^a   Konvalinka, Ana ^a   Zinman, Bernard ^b   Diamandis, Eleftherios P ^c   Soosaipillai, Anton ^c   Reich, Heather ^a   Lorraine, Joanne ^d   Lai, Vesta ^a   Scholey, James W ^a   Miller, Judith A ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; GLUCOSE; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; PROTEIN KINASE C BETA; RUBOXISTAURIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; ENZYME INHIBITION; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ALBUMINURIA; BLOOD PRESSURE; CHEMOKINE CCL2; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; GLOMERULAR FILTRATION RATE; HEMODYNAMICS; HUMANS; INDOLES; KIDNEY; MALEIMIDES; PROTEIN KINASE C;

EID: 64549129226     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-1609     Document Type: Article

References (12)

1. IshiiH,KoyaD,King GL: Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus. J Mol Med 76:21-31, 1998
2. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell SE, Kern TS, Ballas LM, Heath WF, Stramm LE, Feener EP, King GL: Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 272:728 -731, 1996
3. Gilbert RE, Cox A, McNally PG, Wu LL, Dziadek M, Cooper ME, Jerums G: Increased epidermal growth factor in experimental diabetes related kidney growth in rats. Diabetologia 40:778 -785, 1997
4. Tuttle KR: Linking metabolism and immunology: diabetic nephropathy is an inflammatory disease. J Am Soc Nephrol 16: 1537-1538, 2005
5. Giunti S, Tesch GH, Pinach S, Burt DJ, Cooper ME, Cavallo-Perin P, Camussi G, Gruden G: Monocyte chemoattractant protein-1 has prosclerotic effects both in a mouse model of experimental diabetes and in vitro in human mesangial cells. Diabetologia 51:198-207, 2008
6. Cherney DZ, Miller JA, Scholey JW, Bradley TJ, Slorach C, Curtis JR, Dekker MG, Nasrallah R, He'bert RL, Sochett EB: The effect of cyclooxygenase-2 inhibition on renal hemodynamic function in humans with type 1 diabetes. Diabetes 57:688- 695, 2008
7. Sochett EB, Cherney DZ, Curtis JR, Dekker MG, Scholey JW, Miller JA: Impact of renin angiotensin system modulation on the hyperfiltration state in type 1 diabetes. J Am Soc Nephrol 17:1703-1709, 2006
8. Tesch GH, Lan HY, Nikolic-Paterson DJ: Treatment of tissue sections for in situ hybridization. Methods Mol Biol 326:1-7, 2006
9. Tesch GH, Maifert S, Schwarting A, Rollins BJ, Kelley VR: Monocyte chemoattrac-tant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas(lpr) mice. J Exp Med 190:1813-1824, 1999
10. Touyz RM, Schiffrin EL: Role of protein kinase C in the anti-aggregatory effects of endothelin-1 on human platelets. Clin Sci (Lond) 88:277-283, 1995
11. Lee HB, Yu MR, Yang Y, Jiang Z, Ha H: Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J Am Soc Nephrol 14:S241-245, 2003
12. Torres DD, Rossini M, Manno C, Mat-tace-Raso F, D'Altri C, Ranieri E, Pontrelli P, Grandaliano G, Gesualdo L, Schena FP: The ratio of epidermal growth factor to monocyte chemotactic peptide-1 in the urine predicts renal prognosis in IgA nephropathy. Kidney Int 73:327-333, 2008